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Summary  
BACKGROUND  
Vedolizumab is a gut-selective antibody to α4β7 integrin approved to treat moderate-to-severe 
Crohn’s disease and ulcerative colitis in adults. Inflammatory bowel disease (IBD) and 
immunosuppressant use are associated with increased risk of malignancy.  
AIM  
To analyse the incidence of malignancy with vedolizumab treatment in the GEMINI Long-
Term Safety (LTS) study and post-marketing setting.  
METHODS 
Malignancy data from the LTS study (May 2009 to May 2018), and data from the 
vedolizumab Global Safety Database (20-May-2014 to 19-May-2018), were identified using 
Medical Dictionary for Regulatory Activities coding. The number of patients experiencing 
malignancies in the LTS study (excluding malignancies within 1 year following vedolizumab 
initiation) was indirectly standardized against the number expected, using age- and 
sex-specific rates in patients with IBD from Optum’s Clinformatics™ Data Mart (CDM) 
database.   
RESULTS 
Among 1785 patients with ≥1 year of follow-up post-vedolizumab initiation in the LTS study 
(total 5670 patient-years), observed numbers of malignancies were similar to those expected 
compared with CDM data (31 vs 29; ratio of observed: expected events = 1.08; P = 0.71; 
95% confidence intervals [CI] 0.73, 1.53). The most common malignancies were renal and 
bladder (6). Post-marketing, 293 patients reported 299 malignancies (including malignancies 
within 1 year following vedolizumab initiation), in approximately 208,050 patient-years of 
vedolizumab exposure. Lower gastrointestinal malignancies were most common (59).  
CONCLUSIONS 
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The number of malignancies in the LTS study was similar to that expected from an IBD 
population with no statistically significant differences, though few confounders could be 
corrected for. Limitations of post-marketing safety reporting require consideration; however, 
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1. INTRODUCTION 
In patients with Crohn’s disease (CD), it has been estimated that the risk of colorectal, 
upper gastrointestinal (GI), and small bowel cancers is increased 1.9–2.5-fold, 2.9-fold, and 
27.1-fold, respectively, versus the background population.1,2 In patients with ulcerative colitis 
(UC), the risk of colorectal and hepatobiliary cancers is estimated to be 2.4-fold and 2.6-fold 
higher, respectively, than the general population.2,3 No unequivocal excess risk of extra-
intestinal cancer has been established in patients with CD or UC; however, one study found 
increased risk at specific anatomical sites, including lungs, urinary bladder, and skin, in 
patients with CD, and increased risk of leukaemia in patients with UC, but no significant 
increase overall.2 A further study found increased lymphoma rates in men with CD versus 
healthy controls.4 However, estimates were not adjusted for relevant risk factors, such as 
smoking or previous treatment exposure, in either study.  
 
In addition to the impact of underlying disease, it is important to consider the 
possibility of increased risk of malignancy associated with treatments intended to reduce GI 
tract inflammation in CD or UC. Immunomodulators, including thiopurines and biologics 
(such as infliximab and other anti-tumour necrosis factor alpha [TNFα] antibodies), are 
commonly used to treat moderately-to-severely active disease.5 Many treatments have been 
associated with increased malignancy risk in patients with inflammatory bowel disease 
(IBD), notably thiopurines; for example, one meta-analysis found a 4.9-fold increase in the 
incidence of lymphoma.6 Notably, infliximab carries a ‘black box’ warning regarding 
malignancies.7 Furthermore, a population-based cohort study found that long-term 
(> 12 months) immunosuppression was associated with increased risk of haematologic 
cancer, non-Hodgkin lymphoma, squamous cell skin cancer, and overall cancer, primarily 
attributable to thiopurine use.8 In contrast, a registry-based cohort study found no significant 
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increase in cancer risk for patients with IBD receiving anti-TNFα therapy versus no anti-
TNFα therapy over a median follow-up of 3.7 years.9  
 
Vedolizumab is a gut-selective antibody to α4β7 integrin approved to treat moderate-
to-severe active CD or UC in adults.10-12 Integrated safety data from six vedolizumab trials 
have shown a low incidence of malignancy,13 although trial follow-up periods and patient 
numbers were insufficient to evaluate this fully. Since first approval, additional safety data 
reflecting longer-term use of vedolizumab have been collected in an open-label extension 
study (GEMINI Long-Term Safety [LTS] study; NCT00790933)14,15 and the vedolizumab 
Global Safety Database (GSDB), through individual case safety reports from post-marketing 
(PM) sources. Given the importance of understanding malignancy risk associated with IBD 
treatments, this analysis aims to provide further evidence on whether there is an increased 
incidence of malignancy in patients with CD or UC receiving vedolizumab.      
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2. MATERIALS AND METHODS 
2.1. GEMINI long-term safety study data 
Safety data for vedolizumab were collected in the LTS study between May 2009 and 
May 2018. Most patients were recruited from the GEMINI 1, GEMINI 2, and GEMINI 3 
trials, and an open-label phase 2 trial (NCT00619489); all assessed the efficacy and/or safety 
of vedolizumab in patients with CD or UC. Notably, the associated GEMINI inclusion 
criteria stipulated that patients with a prior history of malignancy were not eligible for 
participation. These trials, and the LTS study (using a June 2013 data cut-off), have been 
described previously.13-18 In the LTS study, patients randomized to vedolizumab in 
GEMINI 1, GEMINI 2, and GEMINI 3 continued to receive vedolizumab, whereas patients 
randomized to placebo switched to vedolizumab. The remaining patients, who enrolled 
directly into the LTS study, were vedolizumab-naïve before treatment. Notably, patients 
received 4-weekly infusions of vedolizumab, compared with the usual dosing regimen of 8-
weekly infusions as described in the vedolizumab prescribing information.12 Patients with 
family or personal history of colorectal cancer, those aged > 50 years, or those with another 
known risk factor for colorectal cancer were only included in the LTS study if their colorectal 
cancer surveillance was up-to-date.  
 
The LTS study was conducted in accordance with the ethical principles in the 
Declaration of Helsinki, and all appropriate study documentation was reviewed by the 
institutional review board and independent ethics committee according to local regulations. 
All rollover patients signed consent forms before enrolment; directly enrolled patients signed 
consent forms before commencement of any study-related procedures. All authors had access 
to the relevant study data, and reviewed and approved the final manuscript.  
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 Observed malignancy events 
This report describes all data regarding malignancies gathered from the LTS study 
until 19 May 2018, and includes all patients who received at least one dose of vedolizumab 
by this date. Relevant adverse events (AEs) were identified using Medical Dictionary for 
Regulatory Activities (MedDRA) version 20.0 System Organ Class terms relating to 
neoplasms (excluding benign).  To avoid misclassifying prevalent malignancy, patients with 
a diagnosis of malignancy prior to, or within 1 year after starting treatment with vedolizumab 
were excluded, as were the associated follow-up time and the following events: benign 
neoplasms, basal cell carcinomas, colon adenomas, haemangioma, neurilemmoma, 
non-melanoma skin cancers, and malignancies with diagnoses reported before vedolizumab 
initiation.  Total exposure time in the analysis for patients enrolled in the LTS study was 
measured from 1 year after the date of first vedolizumab infusion in the LTS study or lead-in 
study until the last recorded assessment date for the patient, based on visit dates, dates of 
infusions, and dates of adverse events. Identified malignancies were categorized by 
anatomical site (Supplementary Table 1 provides grouping of MedDRA preferred terms). 
Malignancies were also split by indication for vedolizumab (CD/UC), previous 
immunomodulator exposure (yes/no; including anti-TNFα therapy), and disease duration (≤ 5 
years/> 5 years; defined as the time between disease diagnosis and vedolizumab initiation).  
 
 Expected malignancy events 
For comparison with observed malignancy rates in the LTS study, expected numbers 
of malignancy events in patients with IBD were calculated using indirect standardization, 
with patients with IBD in the US Optum Clinformatics™ Data Mart (CDM) database as a 
reference population. The CDM database is a commercial and Medicare de-identified claims 
database of almost 48 million members. An advantage of the CDM database is that many 
other databases only cover commercial or Medicare supplemental plans. The CDM database 
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contains claims from June 2000 to December 2017, with diagnoses recorded using 
International Statistical Classification of Diseases and Related Health Problems, 9th Revision 
(ICD-9) and ICD-10 codes.  
Individuals in the CDM database with a diagnosis of CD or UC were identified as 
those with at least two different claims associated with CD or UC diagnostic codes (ICD-9: 
556.x or 555.x; ICD-10: K51.x [CD], K50.x [UC]) ≥ 30 days apart. Patients with diagnoses 
of both CD and UC were classified as having “unspecified IBD” and excluded. Malignancies 
in the CDM database were identified using ICD-9 and ICD-10 codes for malignant 
neoplasms (ICD-9: 140.x to 209.x; ICD-10: C00.x to C96.x). To align diagnoses from the 
CDM database as closely as possible with those of interest in the LTS study, benign 
neoplasms, neoplasms of uncertain behaviour, in situ neoplasms, and all skin neoplasms, 
except malignant melanomas, were excluded. To mirror exclusions in the exposed cohort 
from the LTS study, patients with a diagnosis of malignancy recorded within the database at 
any point prior to one year after IBD diagnosis were excluded from the CDM population. The 
start date for the calculation of patient-time in CDM population was assigned as the date one 
year after IBD diagnosis, so that as in the LTS study, the first year of available follow-up was 
censored to avoid misattribution of prevalent malignancies as incident. Following 
identification of relevant malignancies, patient-years of follow-up were estimated. In this 
calculation, index date was defined as the date of the first recorded ICD code of CD or UC. If 
a patient had at least 1 year of follow-up after the IBD index date and did not have a relevant 
malignancy diagnosis, patient-years were calculated using the following formula: 
 
 Number of patient-years = ((last enrolment date – IBD index date + 1) / 365.25) –1 
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If a patient had a relevant malignancy diagnosis and at least 1 year of follow-up, 
patient-years were calculated using the following formula: 
 
 Number of patient-years = ((malignancy diagnosis date – IBD index date + 1) / 
365.25) –1  
 
Using the number of patient-years, rates of malignancy in the reference population 
were calculated for each age (18–39, 40–44, 45–49, 50–54, 55–59, 60–64, 65–69, 70–74, and 
75+ years old) and sex stratum by dividing numbers of events in each stratum by the total 
number of patient-years. The resulting rates in the reference population for each age stratum 
were then multiplied by the total follow-up time for the LTS study population to provide 
estimates of the age- and sex-adjusted expected numbers of malignancies for each anatomical 
site. Finally, the ratio of observed to expected events was calculated, with 95% confidence 
intervals (CIs) and hypothesis tests of equal event rates in the reference and study population 
conducted based on a Poisson distribution of the number of observed events. 
 
2.2. Post-marketing data  
All PM AE reports received by the license holder, Takeda Pharmaceutical Company 
Ltd, since vedolizumab approval are held in the vedolizumab GSDB. Report sources include: 
spontaneous reports from patients, healthcare professionals, and regulatory authorities; 
solicited reports from patient-support and market-research programs; and reports extracted 
from the literature. All PM reports concerning malignancies received between vedolizumab 
approval and 19 May 2018 were identified using the MedDRA version 21.0 System Organ 
Class term “neoplasms benign, malignant, and unspecified (including cysts and polyps)”. For 
consistency with LTS study data, benign neoplasms, colon adenomas, and all malignancies 
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with diagnoses reported before vedolizumab initiation were excluded; however, events 
reported within the first year of vedolizumab exposure were included as a significant number 
of reported malignancies did not contain information on the malignancy diagnosis date. 
Relevant reports identified were then categorized by anatomical site of malignancy 
(Supplementary Table 2), and by indication (CD, UC, unspecified IBD, other, or not 
reported). Patient-years of follow-up were considered equivalent to total dispensed 
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3. RESULTS  
3.1. GEMINI long-term safety study  
 Overview of events and baseline characteristics  
In total, 2243 patients were enrolled into the GEMINI LTS study by the 19 May 2018 
data cut-off, with a median follow-up of 1014 days (2.8 years), generating 7746 patient-years 
of data. Of these, 1822 patients had previously participated in the phase 2 (n = 37), 
GEMINI 1 (n = 675), GEMINI 2 (n = 726), or GEMINI 3 (n = 384) trials. The remaining 421 
patients were vedolizumab-naïve and enrolled directly into the LTS study. Of the 2243 
patients, 1785 had ≥ 1-year follow-up after vedolizumab initiation. In 5670 patient-years of 
included vedolizumab exposure, 31 patients experienced malignancies of interest, 
corresponding to 2% of patients enrolled in the LTS study with follow-up ≥ 1 year after first 
infusion.     
 
When comparing baseline characteristics of the 1785 patients with follow-up ≥ 1 year 
after vedolizumab initiation with those of the entire LTS study population (including those 
with follow-up exclusively < 1 year after vedolizumab initiation; N = 2243), there were no 
substantial differences. Of the 1785 patients with follow-up ≥ 1 year after vedolizumab 
initiation, 880 (49%) were female, versus 14 (45%) of the 31 patients with malignancies 
(Table 1). The mean (standard deviation) age in the LTS study was 39.5 (12.96) years, 
compared with 51.2 (10.50) years for patients experiencing a malignancy. Regarding 
indication, 1034 (58%) had CD and 751 (42%) had UC, while 17 (55%) and 14 (45%) 
patients with a malignancy had CD and UC, respectively. Prior use of anti-TNFα therapy was 
reported by 62% of patients with CD and 43% of patients with UC in the LTS study; in 
patients experiencing a malignancy, these proportions were 65% and 57%, respectively.  
 
27 September 2019 Confidential     
  12 
Malignancies occurring in the highest number of patients were renal and bladder 
(n = 6; 3 CD, 3 UC), lower GI (n = 5; 2 CD, 3 UC [including one patient with UC who 
experienced two events]), and respiratory (n = 4; 1 CD, 3 UC; Table 2). Malignancies at all 
other sites were experienced by three or fewer patients, and malignancy numbers at each site 
were generally similar between patients with CD and those with UC. 
 
 Malignancies by previous immunomodulator exposure (including anti-TNFα 
agent exposure) and disease duration 
In 1293 patient-years of data on patients without prior immunomodulator exposure, 
three patients experienced a malignancy (Table 2), corresponding to 232 events per 
100,000 patient-years. In 4377 patient-years of data on patients with prior immunomodulator 
exposure, 28 experienced a malignancy (Table 2), corresponding to 640 events per 
100,000 patient-years.  
 
In 2196 patient-years of data on patients with disease duration of ≤ 5 years, eight 
patients experienced a malignancy, corresponding to 364 events per 100,000 patient-years. In 
3474 patient-years of data on patients with disease duration > 5 years, 23 experienced a 
malignancy, corresponding to 662 events per 100,000 patient-years.  
 
 Comparison of observed versus expected malignancy events 
The overall number of patients with malignancies observed in the LTS study (n = 31) 
was similar to the expected number estimated using an age- and sex-adjusted reference 
population (n = 29; P = 0.71), corresponding to a ratio of observed to expected events across 
all anatomical sites of 1.08 (95% CI, 0.73–1.53; Figure 1). With respect to individual 
malignancy sites, observed numbers of malignancies did not differ significantly from the 
expected number at any site (Figure 1).  
27 September 2019 Confidential     
  13 
 
3.2. Post-marketing setting 
 Overview of events and baseline characteristics 
In the context of approximately 208,050 patient-years of vedolizumab exposure in the 
PM setting, 299 malignancy events in 293 patients were identified from the vedolizumab 
GSDB, corresponding to 0.4% of all reported AEs (N = 80,218) and approximately 
144 events per 100,000 patient-years; this figure is placed in context in the discussion. Six 
patients reported a malignancy at more than one site. Of the malignancies reported, 
126 (42%) did not contain information on malignancy diagnosis date relative to vedolizumab 
therapy initiation, and 128 malignancies (43%) were reported to occur within 1 year after 
starting vedolizumab treatment. The other 45 malignancies (15%) occurred ≥ 1 year after 
vedolizumab initiation. 
  
Of the 293 patients with reported malignancies, 145 (49%) were female and 
160 (55%) were aged 18–64 years (Table 3). Regarding indication, 129 patients (44%) had 
CD and 116 (40%) had UC. Prior and/or concomitant anti-TNFα therapy, concomitant 
corticosteroid use, and/or other concomitant immunomodulatory therapies were reported in 
47%, 29%, and 20% of patients, respectively (Table 3); 24% of patients did not report using 
these treatments prior to, or concomitantly with, vedolizumab.  
 
 3.2.2. Malignancies by anatomical site and indication 
Across all indications, the most common malignancies were of the lower GI tract and 
lymphoma (59 [20%] and 33 [11%] events, respectively). An unspecified malignant 
neoplasm was reported in 18 patients (6%), and a GI neoplasm of “unspecified” status was 
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reported in one further patient (0.3%), which was included in this analysis because there was 
insufficient information to determine if the neoplasm was benign or malignant.  
 
Numbers of reported malignancies were similar whether patients were receiving 
vedolizumab for CD or UC (134 and 117, respectively). Lower GI malignancies were the 
most commonly reported malignancy in patients with CD or UC (21 and 34, respectively).  
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4. DISCUSSION 
In the LTS study, the number of observed malignancies with vedolizumab was similar 
to the reference population with IBD from the CDM database (ratio of observed to expected, 
1.08; P = 0.71). It must be acknowledged that the standardization performed had limitations. 
Although sex- and age-specific rates were used and patients with a history of malignancy 
prior to starting treatment for vedolizumab, or with a diagnosis of malignancy within 1 year 
following vedolizumab initiation, were excluded, other confounders, such as disease duration 
and receipt of previous immunomodulators, could not be adjusted for. The importance of this 
is highlighted by the fact that 28 of the 31 patients with a malignancy reported previous 
immunomodulator use and 23 of 31 had a disease duration of > 5 years.  
 
In the PM setting, malignancies were reported in 293 patients in 208,050 patient-years 
(approximately 144 events per 100,000 patient-years), indicating no signal of increased risk 
of malignancy in patients with IBD receiving vedolizumab in the real-world setting. 
However, this should be interpreted in the context of the inherent biases of PM data sources, 
including that voluntary reporting means not all malignancy events are necessarily captured. 
Crude comparisons suggest the rate in the PM setting is substantially lower than reported 
from other sources, including the LTS study (approximately 547 events per 100,000 patient-
years), and by Bernstein et al.4 in a study linking a population-based IBD database to a 
comprehensive cancer registry to determine cancer incidence among a North American 
population with IBD between 1984 and 1997 (690 events per 100,000 patient-years). In 
addition, because 47% of patients reporting malignancies in the current study had prior or 
concomitant exposure to anti-TNFα agents and 20% reported concomitant use of other 
immunomodulatory therapies, prior or concomitant treatment may have contributed to their 
risk of malignancy.  
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The most common sites of malignancy in the LTS study were renal and bladder, 
lower GI, and respiratory. The observed numbers of malignancies in these sites were not 
significantly higher than expected based on the CDM reference population with IBD 
(P > 0.05 for each). However, patient numbers were no greater than six for any malignancy 
site, hence there was very limited power to detect any relationship to an individual 
malignancy. In the PM setting, the most frequently reported cancers were GI (21 and 
34 events in patients with CD or UC, respectively). These cancers are well documented in 
patients with IBD,19 and are reported to be the most frequently occurring malignancies in this 
population.1-4  
 
In the LTS study, the number of patients with lower GI malignancies (n = 5) was 
similar to the number expected based on indirect standardization against the CDM reference 
population (ratio, 1.06; P = 1.00). However, the low number of events, and therefore limited 
power, again requires consideration when interpreting the result. In the PM setting, the 
unadjusted rate of lower GI malignancies equated to 28.4 per 100,000 patient-years. In the 
Surveillance, Epidemiology, and End Results (SEER) registry, overall age-adjusted incidence 
of colorectal cancers in the general population was 40.1 per 100,000 people per year.20 In 
studies of patients with IBD, Bernstein et al. found overall incidences of 146 and 44 per 
100,000 person-years for colon and rectal cancer, respectively,4 and Soderlund et al. reported 
an overall incidence of 95 cases of colorectal cancer per 100,000 person-years.21 Although 
these datasets incorporated preferred terms relating to slightly different sites than considered 
in the PM setting reported here, and we have not standardised these figures for age and sex, 
incidence of lower GI malignancies seen with vedolizumab in the PM setting appears low. 
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These data reflect large numbers of patient-years from the LTS study and PM setting. 
The LTS study used stringent eligibility criteria, and recorded detailed, consistent data on 
events, patient characteristics, and treatment histories.22 However, there are a number of 
limitations that should be acknowledged. 
This study included a relatively small proportion of patients, who consented to 
involvement in the clinical trial with strict eligibility criteria, so results may be less 
generalizable to real-world setting patients. Our analysis also used a patient population with 
IBD from the CDM database as a reference population. However, our methodology of 
indirect standardization does not allow correction for all confounders (e.g. differences in IBD 
severity, duration, activity and extent of colitis and medication history), despite adjusting for 
the effects of age and gender. On the other hand, as biologic medications such as 
vedolizumab are likely to be given to patients with disease of greater than average severity, it 
is the authors’ belief that, were these data available to allow correction, the expected number 
of malignancies would likely increase rather than reduce. Therefore, we do not believe the 
use of the CDM database as a reference population invalidates the findings of this study.   
Although, where a history of malignancy prior to starting IBD treatment or a 
diagnosis of malignancy within 1 year following treatment initiation were recorded, patients 
were excluded, the CDM database lacks full medical histories of patients, and thus only 
events occurring after joining the database are recorded. Cancer diagnoses made prior to 
inclusion in the database are therefore not recorded and patients may not be excluded 
appropriately, which could bias the number of cases identified. In addition, disease severity 
of patients in the CDM database (all IBD severities) may not reflect that of patients in the 
LTS study (moderate-to-severe active IBD). However, as no precisely comparable IBD 
population of patients not treated with vedolizumab was available, we considered the CDM 
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reference population the most suitable for this analysis to which we could gain access and so 
chose to accept this bias.  
Another common source of comparators in such studies is a high quality general 
population malignancy database such as the SEER registry.23 However, the SEER registry 
includes general, rather than IBD-specific population data, and consequently reflects the risks 
of malignancy in the general population, which are lower than those of IBD patients.1-3 
Furthermore, the SEER registry, as it provides data on cancer incidence in the general 
population, does not easily allow for the generation of rates excluding those with previous 
malignancy or with malignancy diagnoses within 1 year of treatment initiation as we have 
attempted.  
There were substantially more patient-years of exposure in the PM setting than in the 
LTS study, and these data more closely reflect vedolizumab use in real-world clinical 
practice. The vedolizumab GSDB includes important patient information (e.g. age, treatment 
history, and indication), but this was incomplete for some patients. In addition, although most 
malignancies were new events, a small number may have resulted from exacerbations or 
metastases of malignancies reported in the GEMINI trials. Reporting to the vedolizumab 
GSDB is voluntary, meaning that the number reported here is likely to be lower than if all 
malignancies in the PM setting were reported. However, bias, such as increased reporting of 
more serious events (including malignancies), associated with PM data should be considered. 
There are also multiple confounding factors that may affect risk of malignancy in patients 
with IBD, including disease duration, age at diagnosis, extent of disease, inflammation 
severity, treatment history, history of malignancy, and smoking history, which are incomplete 
in some PM data reports.19 Finally, the duration of vedolizumab exposure in these patients is 
still relatively short.  
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In conclusion, the LTS study demonstrated that the total number of observed 
malignancies was similar to that expected after standardizing against patients with IBD in the 
CDM database, with patients in the LTS study receiving 4-weekly infusions of vedolizumab 
as opposed to the usual 8-weekly infusion regimen. The significance of malignancy rates at 
specific sites should not be overinterpreted because of low numbers of events observed. 
Allowing for limitations of PM safety reports, the number of malignancies with vedolizumab 
use appeared low. Safety data on malignancy incidence from the LTS study and PM setting 
suggest the favourable malignancy-related safety profile of vedolizumab in CD and UC 
observed in pre-approval clinical trials is retained with longer-term use. Although limitations 
of these data sources must be considered, these data show no evidence of any significant 
increase in incidence of malignancy in patients with IBD receiving vedolizumab. Additional 
data on incidence of malignancy with vedolizumab use will be available from the post-
authorization safety study (PASS). PASS is a prospective, observational trial which is 
currently being conducted at multiple centres worldwide (NCT02674308). It aims to examine 
the long-term safety of vedolizumab versus other biologic agents in approximately 5000 
participants with CD or UC (with a follow-up period duration of 7 years). Data from this 
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Table 1. Baseline characteristics of GEMINI LTS study patients 
 
Patients with at least 1 year of vedolizumab 
exposure  




(n = 1034) 
Ulcerative 
colitis 
(n = 751) 
Total 
 
(N = 1785) 
Crohn’s 
disease 
(n = 17) 
Ulcerative 
colitis 
(n = 14) 
Total 
 
(N = 31) 
Sex, female, n (%) 549 (53) 331 (44) 880 (49) 9 (53) 5 (36) 14 (45) 
Age, years 







Median  36.8 40.8 38.1 52.7 49.7 52.1 


























Duration of disease, years       
Mean (SD) 10.0 (8.42) 8.0 (6.79) 9.2 (7.83) 12.9 (10.36) 10.5 (9.78) 11.8 (10.01) 
Median 7.8 5.8 6.8 8.9 7.0 7.8 
Baseline disease activity, mean (SD)       
Partial Mayo score – 3.8 (2.91) – – 3.9 (3.34) – 
Harvey–Bradshaw Index score 7.3 (4.89) – – 8.2 (4.48) – – 
 
Smoking history, n (%)       
Current smoker 275 (27) 39 (5) 314 (18) 7 (41) 0 (0) 7 (23) 
Former smoker  254 (25) 218 (29) 472 (26) 4 (24) 5 (36) 9 (29) 
Never smoked 499 (48) 466 (62) 965 (54) 6 (35) 9 (64) 15 (48) 
27 September 2019 Confidential     
  25 
Unknown/missing data 6 (1) 28 (4) 34 (2) – – – 
Treatment history, n (%)        
Prior anti-TNFα therapy 640 (62) 321 (43) 961 (54) 11 (65) 8 (57) 19 (61) 
Any prior anti-TNFα therapy 
failure† 598 (58) 290 (39) 888 (50) 10 (59) 7 (50) 17 (55) 
Concomitant immunomodulatory 
therapy  317 (31) 204 (27) 521 (29) 8 (47) 4 (29) 12 (39) 
Concomitant corticosteroid therapy 452 (44) 314 (42) 766 (43) 7 (41) 8 (57) 15 (48) 
LTS, Long-Term Safety; SD, standard deviation; TNFα, tumour necrosis factor alpha 
†Patients reporting any prior anti-TNFα therapy failure are a subset of those reporting prior anti-TNFα therapy. 
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Table 2. Numbers of GEMINI LTS study patients with malignancy events by indication, previous immunomodulator exposure, and disease 
duration  













Duration of disease 
≤ 5 years 
(2196 PY) 
Duration of disease 
> 5 years 
(3474 PY) 
Breast 1 1 2 0 0 2 
Central nervous system 0 2 2 0 0 2 
Gynaecologic 1 0 1 0 0 1 
Hepatic 2 0 2 0 1 1 
Lower gastrointestinal 2 3† 5† 0 0 5† 
Lymphoma 1 0 1 0 1 0 
Mouth and throat 1 0 1 0 1 0 
Multiple myeloma 1 0 1 0 1 0 
Prostate 1 1 1 1 1 1 
Renal and bladder 3 3 4 2 2 4 
Respiratory 1 3 4 0 1 3 
Soft tissue sarcomas 1 0 1 0 0 1 
Thyroid 2 1 3 0 0 3 
All cancers 17 14 28 3 8 23 
LTS, Long-Term Safety; PY, patient-years 
†
Including one patient who experienced two events.  
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Table 3. Baseline characteristics of patients experiencing malignancies in the post-marketing setting 
 Indication, n (%)  



































































































































TNFα, tumour necrosis factor alpha 
†Vedolizumab is not approved for the treatment of patients < 18 years old. 
‡Including two patients with graft-versus-host disease. 
§Excluding anti-TNFα therapies, because these data are presented separately.
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Figure legends 
Figure 1. Indirect standardization of the numbers of GEMINI LTS Study patients with 
malignancy events by anatomical site. 
 
Data shown exclude malignancies with a diagnosis reported prior to, or within 1 year after starting treatment 
with vedolizumab and the following events: benign neoplasms, basal cell carcinomas, colon adenomas, 
haemangioma, neurilemmoma, non-melanoma skin cancers, and malignancies with diagnoses reported before 
vedolizumab initiation. 
CI, confidence interval; LTS, Long-Term Safety 
*P < 0.05. 
†Malignancies were identified using Medical Dictionary for Regulatory Activities version 20.0 System Organ 
Class term “neoplasms benign, malignant, and unspecified (including cysts and polyps)”. Benign neoplasms, 
basal cell carcinoma, colon adenoma, haemangioma, neurilemmoma, all non-melanoma skin cancers, and 
malignancies with diagnoses reported before, or within 1 year after, the start of vedolizumab treatment (i.e. 
those in patients who received placebo in the lead-in studies) were excluded. The corresponding follow-up time 
for excluded malignancies was not used in the analysis. 
‡Patients with more than one malignancy at a single site were counted only once. 
§The expected number of patients with malignancies in the GEMINI LTS study was estimated by indirectly 
standardizing against age- and sex-specific malignancy rates in patients with inflammatory bowel disease in 
Optum’s Clinformatics Data Mart database. 
¶Survival time was measured up to time of failure or end of study follow-up. As a result, the total number of 
patient-years is reduced vs values of each site individually. 
 
 
